Genome-wide Epistasis for Cardiovascular Severity in Marfan Study

Status: Recruiting
Location: See location...
Intervention Type: Genetic
Study Type: Observational
SUMMARY

Marfan syndrome (MFS) is an autosomal dominant connective tissue disorder with pleiotropic manifestations in the ocular, skeletal and cardiovascular systems. Morbidity and mortality are mostly determined by aortic root aneurysm dissection and rupture. Although mutations in FBN1, the gene coding for the extracellular matrix protein fibrillin-1, are the well-established genetic cause of this condition, there is a very poor correlation between the nature or location of the causal FBN1 mutation and the phenotypical outcome. Indeed, wide intra- and interfamilial phenotypical variability is observed. So, even with an identical primary mutation in all family members, the clinical spectrum varies widely, from completely asymptomatic to sudden death due to aortic dissection at a young age. The precise mechanisms underlying this variability remain largely elusive. Consequently, a better understanding of the functional effects of the primary mutation is highly needed and the identification of genetic variation that modifies these effects is becoming increasingly important. In this project, we have carefully selected different innovative strategies to discover mother nature's own modifying capabilities with respect to Marfan syndrome aortopathy.

Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: f
View:

• Participants with proven mutation (p.Ile2585Thr;c.7754C\>T) in the FBN1 gene

Locations
Other Locations
Belgium
University Hospital Antwerp
RECRUITING
Edegem
Contact Information
Primary
Bart Loeys, Prof,MD,PhD
bart.loeys@uantwerpen.be
++32-3-2759768
Backup
Paul Coucke, Prof,PhD,Ing
paul.coucke@ugent.be
++32-9-3323634
Time Frame
Start Date: 2020-11-30
Estimated Completion Date: 2025-10-31
Participants
Target number of participants: 200
Treatments
AMC (Affected Mutation Carrier)
FBN1 mutation (Marfan Syndrome) - Phenotype cardiovascular severe outcome
UMC (Unaffected Mutation Carrier)
FBN1 mutation (Marfan Syndrome) - Phenotype cardiovascular mild outcome
Related Therapeutic Areas
Sponsors
Leads: University Hospital, Antwerp
Collaborators: University Hospital, Ghent

This content was sourced from clinicaltrials.gov